Jimenez: "Huge Sense Of Urgency" To Implement Outcomes-Based Systems In Europe
Joe Jimenez, CEO of Novartis and EFPIA president talks about why the acceleration towards an outcomes-based healthcare system is so important to Europe, and to the reputation of the pharmaceutical industry.
You may also be interested in...
Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.
Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.
Pharmaceutical industry associations have until recently remained pretty quiet over the prospect of a British exit from the EU. But following the announcement that the referendum will be held on June 23, that seems to be changing.